Osmotica Pharmaceuticals plc (OSMT) Preliminary Results Fail to Beat Placebo On March 27, 2019, after the markets closed, Osmotica Pharmaceuticals plc (OSMT) announced preliminary results for a second Phase 3

Amyris, Inc. (AMRS) Accused of Making Materially False And Misleading Statements According to the complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between

OSI Systems, Inc. (OSIS) Systems Accused of Obtaining Major Contract Through Bribery On December 6, 2017, Muddy Waters Research published a report on OSI entitled “OSIS: Rotten to the Core.” The

Robbins LLP Is Investigating the Officers and Directors of iRhythm Technologies, Inc. (IRTC) on Behalf of Shareholders April 9, 2019 (San Diego, CA & San Francisco, CA) – Shareholder rights

Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misrepresenting Enrollment for Its Drug Trial According to the complaint against the company’s officers and directors for alleged violations of the Securities Exchange Act

Bristow Group Inc. (BRS) Sued for Misleading Shareholders Reveals Material Weakness in Internal Controls According to the complaint against the company for alleged violations of the Securities and Exchange Act

AT&T Inc. (T) Accused of Filing False Registration Statements According to the complaint against the company for alleged securities law violations relating to the company’s registration statement issued in connection

Health Insurance Innovations, Inc. (HIIQ) Accused of Engaging in Insurance Fraud According to the complaint against Health Insurance Innovations, Inc. (Nasdaq: HIIQ) for alleged violations of the Securities Exchange Act

Corbus Pharmaceutical Holdings, Inc. (CRBP) Accused of Faking Clinical Results for Lenabasum According to the complaint against the company for alleged violations of the Securities and Exchange Act of 1934